Tianjin Lisheng Pharmaceutical Co Ltd (002393) - Total Assets
Based on the latest financial reports, Tianjin Lisheng Pharmaceutical Co Ltd (002393) holds total assets worth CN¥5.53 Billion CNY (≈ $809.66 Million USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore Tianjin Lisheng Pharmaceutical Co Ltd debt service capacity to assess how comfortably operating cash covers total debt obligations.
Tianjin Lisheng Pharmaceutical Co Ltd - Total Assets Trend (2006–2025)
This chart illustrates how Tianjin Lisheng Pharmaceutical Co Ltd's total assets have evolved over time, based on quarterly financial data. See 002393 net assets for net asset value and shareholders' equity analysis.
Tianjin Lisheng Pharmaceutical Co Ltd - Asset Composition Analysis
Current Asset Composition (December 2025)
Tianjin Lisheng Pharmaceutical Co Ltd's total assets of CN¥5.53 Billion consist of 59.6% current assets and 40.4% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 27.5% |
| Accounts Receivable | CN¥535.33 Million | 9.6% |
| Inventory | CN¥215.11 Million | 3.9% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥141.35 Million | 2.5% |
| Goodwill | CN¥70.36 Million | 1.3% |
Asset Composition Trend (2006–2025)
This chart illustrates how Tianjin Lisheng Pharmaceutical Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Tianjin Lisheng Pharmaceutical Co Ltd (002393) total market value.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Tianjin Lisheng Pharmaceutical Co Ltd's current assets represent 59.6% of total assets in 2025, a decrease from 61.1% in 2006.
- Cash Position: Cash and equivalents constituted 27.5% of total assets in 2025, up from 19.8% in 2006.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 3.0% of total assets, a decrease from 5.0% in 2006.
- Asset Diversification: The largest asset category is accounts receivable at 9.6% of total assets.
Tianjin Lisheng Pharmaceutical Co Ltd Competitors by Total Assets
Key competitors of Tianjin Lisheng Pharmaceutical Co Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Alkem Laboratories Limited
NSE:ALKEM
|
India | Rs202.87 Billion |
|
Beijing Tongrentang Co Ltd
SHG:600085
|
China | CN¥31.82 Billion |
|
Jiangsu Nhwa Pharmaceutical Co Ltd
SHE:002262
|
China | CN¥9.64 Billion |
|
Jilin Aodong Pharmaceutical Group Co Ltd
SHE:000623
|
China | CN¥35.27 Billion |
|
Fujian Cosunter Pharmaceutical Co Ltd
SHE:300436
|
China | CN¥1.41 Billion |
|
Beijing New Oriental Star Petrochemical Engineering Co Ltd
SHE:002755
|
China | CN¥4.44 Billion |
|
Zhejiang Medicine Co Ltd
SHG:600216
|
China | CN¥14.18 Billion |
|
Shandong Buchang Pharmaceuticals Co Ltd
SHG:603858
|
China | CN¥19.57 Billion |
Tianjin Lisheng Pharmaceutical Co Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 4.52 | 4.33 | 4.38 |
| Quick Ratio | 4.22 | 4.02 | 3.89 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥2.57 Billion | CN¥2.36 Billion | CN¥1.77 Billion |
Tianjin Lisheng Pharmaceutical Co Ltd - Advanced Valuation Insights
This section examines the relationship between Tianjin Lisheng Pharmaceutical Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.11 |
| Latest Market Cap to Assets Ratio | 0.12 |
| Asset Growth Rate (YoY) | -3.5% |
| Total Assets | CN¥5.58 Billion |
| Market Capitalization | $656.92 Million USD |
Valuation Analysis
Below Book Valuation: The market values Tianjin Lisheng Pharmaceutical Co Ltd's assets below their book value (0.12x), which may indicate investor concerns about asset quality or future growth.
Slight Asset Contraction: Tianjin Lisheng Pharmaceutical Co Ltd's assets decreased by 3.5% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for Tianjin Lisheng Pharmaceutical Co Ltd (2006–2025)
The table below shows the annual total assets of Tianjin Lisheng Pharmaceutical Co Ltd from 2006 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥5.58 Billion ≈ $817.17 Million |
-3.48% |
| 2024-12-31 | CN¥5.79 Billion ≈ $846.60 Million |
+0.08% |
| 2023-12-31 | CN¥5.78 Billion ≈ $845.88 Million |
+9.25% |
| 2022-12-31 | CN¥5.29 Billion ≈ $774.25 Million |
+1.93% |
| 2021-12-31 | CN¥5.19 Billion ≈ $759.60 Million |
+3.36% |
| 2020-12-31 | CN¥5.02 Billion ≈ $734.90 Million |
-4.75% |
| 2019-12-31 | CN¥5.27 Billion ≈ $771.56 Million |
+34.60% |
| 2018-12-31 | CN¥3.92 Billion ≈ $573.21 Million |
+6.39% |
| 2017-12-31 | CN¥3.68 Billion ≈ $538.80 Million |
+5.63% |
| 2016-12-31 | CN¥3.49 Billion ≈ $510.07 Million |
+2.24% |
| 2015-12-31 | CN¥3.41 Billion ≈ $498.91 Million |
+4.98% |
| 2014-12-31 | CN¥3.25 Billion ≈ $475.26 Million |
+0.80% |
| 2013-12-31 | CN¥3.22 Billion ≈ $471.49 Million |
+9.79% |
| 2012-12-31 | CN¥2.93 Billion ≈ $429.45 Million |
+2.53% |
| 2011-12-31 | CN¥2.86 Billion ≈ $418.83 Million |
+4.95% |
| 2010-12-31 | CN¥2.73 Billion ≈ $399.08 Million |
+209.16% |
| 2009-12-31 | CN¥882.13 Million ≈ $129.08 Million |
+18.35% |
| 2008-12-31 | CN¥745.35 Million ≈ $109.07 Million |
-14.73% |
| 2007-12-31 | CN¥874.11 Million ≈ $127.91 Million |
+1.23% |
| 2006-12-31 | CN¥863.49 Million ≈ $126.36 Million |
-- |
About Tianjin Lisheng Pharmaceutical Co Ltd
Tianjin Lisheng Pharmaceutical Co.,Ltd. engages in the research and development, production, and sale of pharmaceutical products in China and internationally. The company offers pharmaceutical, traditional Chinese medicine, and antibiotic products in various forms, such as oral solid dosage forms, soft capsules, sterile preparations, and raw materials primarily for cardiovascular and digestive sy… Read more